SCHEMBL4870358

SCHEMBL4870358

COC(=O)CCCCCCCCCCCNC(=O)C(O)CCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.43
PTGFR P43088 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
HDAC1 Q13547 3/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
HDAC3 O15379 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
SLC6A5 Q9Y345 2/20 0.40
PLAAT3 P53816 1/20 0.40
PLAAT5 Q96KN8 1/20 0.40
PLAAT2 Q9NWW9 1/20 0.40
PLAAT4 Q9UL19 1/20 0.40
LMNA P02545 1/20 0.39
TACR1 P25103 1/20 0.38
TGM2 P21980 1/20 0.38
PPARA Q07869 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4873796 0.87 PTGFR (0.53) HRH3PTGFRHDAC1HDAC8HDAC6
SCHEMBL4879965 0.81 NAAA (0.49) HDAC1HDAC8HDAC6HDAC3HDAC2
SCHEMBL28191870 0.79 HDAC1 (0.57) HRH3MEN1KMT2AHDAC1HDAC8
SCHEMBL6864427 0.78 HDAC1 (0.55) MEN1KMT2AHDAC1HDAC8PLAAT3
SCHEMBL14555980 0.76 SCN8A (0.51) HDAC1HDAC8HDAC6HDAC3HDAC2
SCHEMBL4874708 0.75 EPHX2 (0.47) HRH3PTGFRHDAC1HDAC8HDAC6
SCHEMBL853787 0.75 FFAR1 (0.54) HRH3MEN1KMT2AHDAC1HDAC8
SCHEMBL4780592 0.74 CYP2D6 (0.55) KMT2ALMNA
SCHEMBL4780368 0.73 KMT2A (0.53) KMT2ALMNA
SCHEMBL23176840 0.72 HDAC1 (0.44) MEN1KMT2AHDAC1HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-21 US disclosed
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-21 US disclosed
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-21 US disclosed
WO-2008073623-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, NCEH1 HRH3 87/4885PTGFR 340/4885MEN1 4501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.